One molecule, three receptors
Retatrutide is a single 39-amino-acid peptide whose sequence has been engineered so that it fits the binding pockets of three different class B G-protein-coupled receptors: the GIP receptor, the GLP-1 receptor and the glucagon receptor. All three signal mainly through Gαs and cyclic AMP, but they sit on different tissues and produce different downstream effects. The molecule's backbone is derived from GIP, with an exendin-4-like tail that improves GLP-1 receptor binding and mid-chain substitutions that switch on glucagon receptor activity. A C20 fatty diacid on lysine 17 binds serum albumin, which is what gives it a roughly 6-day half-life and once-weekly dosing.
The GLP-1 receptor: the foundation
This is the pathway shared with semaglutide and liraglutide. GLP-1 receptors on pancreatic β-cells amplify insulin secretion only when glucose is elevated, which is why the class rarely causes hypoglycaemia on its own; receptors on α-cells suppress glucagon release after meals; receptors in the stomach slow gastric emptying; and receptors in the hypothalamus, hindbrain and vagal afferents reduce hunger and food reward. Retatrutide's GLP-1 receptor activity is somewhat lower than native GLP-1's — a deliberate choice, since it does not need to carry the whole effect alone.
The GIP receptor: the second incretin
GIP is the other gut hormone released after meals, and its receptor is found on β-cells, adipocytes and neurons. Activation adds to glucose-dependent insulin secretion, influences how fat tissue stores and releases lipids, and — through receptors in the brain — appears to reduce food intake and to blunt the nausea that GLP-1 receptor activation produces. This is the mechanism tirzepatide added to the class, and retatrutide is GIPR-favouring in vitro: of its three activities, the GIP receptor is the one it engages most strongly.
The glucagon receptor: the new element
Glucagon is the hormone that raises blood glucose when you have not eaten, but it does more than that. Glucagon receptor activation in the liver increases fat oxidation and reduces stored liver fat; in the body as a whole it raises energy expenditure — calories burned at rest — and it independently reduces food intake. Those effects are what GLP-1 and GIP agonism cannot provide, and they are the mechanistic explanation for why retatrutide's weight loss exceeded the dual agonists in phase 2 and why its MASLD substudy reported such large liver-fat reductions. The cost is that glucagon also raises glucose and heart rate.
| Receptor | Main tissues | Effect | Shared with |
|---|---|---|---|
| GLP-1R | β-cells, α-cells, stomach, brain | Insulin ↑ (glucose-dependent), glucagon ↓, gastric emptying ↓, appetite ↓ | Semaglutide, liraglutide, tirzepatide |
| GIPR | β-cells, adipose, brain | Insulin ↑, adipose signalling, appetite ↓, nausea mitigation | Tirzepatide |
| GCGR | Liver, adipose, brain | Energy expenditure ↑, liver fat ↓, appetite ↓; glucose ↑ and heart rate ↑ as side effects | Survodutide, mazdutide |
Why the balance is deliberately unequal
If glucagon receptor activity were as strong as the incretin activities, blood glucose would rise. Lilly's designers set the potency ratio so that retatrutide is most active at the GIP receptor, somewhat less at the GLP-1 receptor and least at the glucagon receptor. The two incretin activities drive enough insulin secretion and glucagon suppression to more than cancel the glucose-raising effect of the glucagon component, while the glucagon component still delivers its energy-expenditure and liver effects. The phase 2 diabetes trial confirmed the arithmetic: HbA1c fell by up to about 2 percentage points at the highest dose, and the phase 3 TRANSCEND-T2D-1 trial reported reductions of 1.7–1.9 points versus 0.8 with placebo.
Downstream: what the person experiences
Mechanism translates into effects in a recognisable order. Reduced appetite and earlier fullness appear within the first weeks and scale with dose. Post-meal glucose flattens as insulin rises and gastric emptying slows. Body weight falls steadily — in phase 2, still declining at 48 weeks, which suggests the plateau sits later than for single agonists. Liver fat drops substantially. Resting heart rate rises by a few beats per minute, peaking around 24 weeks and then easing. The gastrointestinal side effects — nausea, diarrhoea, vomiting, constipation — are the same mechanism that suppresses appetite, expressed too strongly, which is why every trial escalated the dose gradually.
How the trials line up with the mechanism
Phase 2 in obesity (NEJM 2023) produced dose-dependent weight loss of −8.7% to −24.2% at 48 weeks, larger than the dual agonist tirzepatide's −20.9% at 72 weeks in SURMOUNT-1 (different trials), consistent with the added glucagon component. The MASLD substudy reported that most participants at higher doses reached normal liver-fat levels, consistent with hepatic glucagon receptor action. Heart rate rose dose-dependently, as glucagon agonism predicts. And glucose fell rather than rose in both diabetes trials, confirming the receptor balance. What the mechanism cannot tell you is long-term safety or cardiovascular outcomes; those are the questions the phase 3 programme and the TRIUMPH-Outcomes trial exist to answer.
What retatrutide is not
It is not a stimulant, a thyroid hormone or a fat blocker; it does not work by increasing metabolism in the sense of a thermogenic supplement, although the glucagon component does raise energy expenditure modestly. It is not a “GLP-3” — no such hormone exists. And it is not approved: as of September 2026 it is in phase 3 trials and a pre-approval expanded-access programme, and anything sold online under the name is unlicensed material whose contents cannot be assumed to have this mechanism, or any mechanism, at all.
Sources and what they cover
These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.
- Li et al. (2024) — Structural basis of retatrutide triple-receptor agonism
Structural receptor research; biological plausibility is separate from proven clinical benefit.
Relevant sections: One molecule, three receptors · The GLP-1 receptor: the foundation · The GIP receptor: the second incretin · The glucagon receptor: the new element · Why the balance is deliberately unequal
- Jastreboff et al. (2023) — Retatrutide for obesity, phase 2 trial
Phase 2 obesity trial: studied regimens, weight and adverse events. Trial doses are not instructions for personal use.
Relevant sections: Downstream: what the person experiences · How the trials line up with the mechanism
- Rosenstock et al. (2023) — Retatrutide in type 2 diabetes, phase 2 trial
Phase 2 diabetes trial; its glycemic endpoints, participants and regimens differ from the obesity study.
Relevant sections: How the trials line up with the mechanism
FAQ
How does retatrutide work?+
It activates three receptors at once. GLP-1 and GIP receptor activity boost glucose-dependent insulin, slow gastric emptying and reduce appetite; glucagon receptor activity raises energy expenditure and burns liver fat. The three are balanced so glucose falls overall.
What does retatrutide do to the body?+
It reduces appetite, slows stomach emptying, increases insulin release when glucose is high, raises resting energy expenditure and reduces liver fat. In phase 2 that produced up to −24.2% body weight at 48 weeks.
Why does retatrutide activate the glucagon receptor if glucagon raises blood sugar?+
Because glucagon also raises energy expenditure and burns liver fat. The incretin activities are set stronger than the glucagon activity, so the net effect on glucose is a reduction — confirmed in both diabetes trials.
Is retatrutide's mechanism the same as tirzepatide's?+
Tirzepatide covers two of the three receptors (GIP and GLP-1). Retatrutide adds the glucagon receptor, which is the source of its extra energy-expenditure and liver effects and of its heart-rate signal.
How long does retatrutide stay in the body?+
Its half-life is about 6 days, so it is dosed once weekly and takes roughly 4–5 weeks to reach steady state or to wash out.